UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
January 23, 2019
Commission File Number: 001 - 38178
Zealand Pharma A/S
(Exact Name of Registrant as Specified in Its Charter)
Smedeland 36
2600 Glostrup (Copenhagen)
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Zealand Pharma A/S, or the Company, dated January 23, 2019, announcing changes to the executive management of Zealand Pharma. Following the resignation of Britt Meelby Jensen on 26 November 2018, the Board of Directors has decided that Britt will be released from her duties as President and CEO as of 28 February 2019.
Adam Steensberg, MD, Executive Vice President and Chief Medical and Development Officer is appointed interim CEO as of 1 March 2019, while also maintaining his current responsibilities.
After nine years of dedicated service, Mats Blom, Chief Financial Officer, will leave Zealand end March 2019.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Zealand Pharma A/S | ||
|
| ||
|
By: |
/s/ Mats Blom | |
|
| ||
|
|
Name: |
Mats Blom |
|
|
Title: |
Chief Financial Officer |
Date: January 23, 2019 |
|
|
|
Company announcement No. 1/2019
Changes to Zealand Pharmas Executive Management |
Copenhagen, Denmark, January 23, 2019 Zealand Pharma A/S today announced changes to its Executive Management.
Following the resignation of Britt Meelby Jensen on 26 November 2018, the Board of Directors has decided that Britt will be released from her duties as President and CEO as of 28 February 2019.
Adam Steensberg, MD, Executive Vice President and Chief Medical and Development Officer is appointed interim CEO as of 1 March 2019, while also maintaining his current responsibilities.
After nine years of dedicated service, Mats Blom, Chief Financial Officer, will leave Zealand end March 2019.
Martin Nicklasson, Chairman of Zealand, comments:
Zealand is in a strong financial position with an exceptional outlook for the coming years. Although I am sad to see both Britt and Mats leave, an experienced and capable Management team is in place to deliver on the strategy and opportunities ahead. I am thankful for Britts and Mats contributions to Zealand. Under their leadership, Zealand has transformed into a company with a late-stage proprietary pipeline, a highly competent organization, a dual listing and physical presence in the U.S. as well as multiple future value drivers. I wish them both the best in their future endeavors.
The Board initiated an international search for a new President and CEO end November 2018 and the process is progressing according to plan, with a short list of candidates being interviewed. A search for a new CFO has been initiated.
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com
Mats Blom, Executive Vice President, Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealands current pipeline
of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealands portfolio also includes two clinical license collaborations with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Companys business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.